Quantifying your body: A how-to guide from a systems biology perspective

Biotechnology Journal

Volumn 7, Issue 8, 2012, Pages 980-991

  Smarr, Larry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL MEASUREMENTS; COMPUTER SCIENTISTS; DIGITAL TRANSFORMATION; MEDICAL COMMUNITY; MEDICAL PROFESSIONALS; MEDICAL RECORD; PARADIGM SHIFTS; PERSONAL EXPERIENCE; SYSTEMS BIOLOGY;

DIGITAL DEVICES; HEALTH CARE; SOCIETIES AND INSTITUTIONS;

BIOLOGY;

ARTICLE; EXERCISE; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; INFLAMMATION; MEDICAL RECORD; MEDICAL TECHNOLOGY; NUTRITION; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SELF EVALUATION; SLEEP; STRESS; SYSTEMS BIOLOGY;

BIOLOGICAL MARKERS; GENOME, HUMAN; HEALTH PROMOTION; HUMANS; INDIVIDUALIZED MEDICINE; METAGENOME; SELF-ASSESSMENT; SYSTEMS BIOLOGY;

EID: 84864806354     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201100495     Document Type: Article

References (64)

1. Fan, R., Vermesh, O., Srivastava, A., Yen, B. K., Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat. Biotechnol 2008, 26, 1373-1378.
2. Mirnezami, R., Nicholson, J., Darzi, A., Preparing for precision medicine. N. Engl. J. Med. 2012, 366, 489-491.
3. Topel, E., The Creative Destruction of Medicine: How the Digital Revolution will Create Better Health Care, Basic Books, 2012.
4. Hood, L., Flores, M., A Personal View on Systems Medicine and the Emergence of Proactive P4 Medicine: Predictive, Preventive, Personalized and Participatory. N. Biotechnol. 2012, DOI: 10.1016/j.nbt.2012.03.004.
5. Duncan, D. E., Experimental Man: What One Man's Body Reveals about His Future, Your Health, and Our Toxic World, Wiley, New York 2009.
6. Flegal, K. M., Carroll, M. D., Ogden, C. L., Curtin, L. R., Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303, 235-241.
7. Traver, K., Kelly Sargent, B., The Program: The Brain-Smart Approach to the Healthiest You, Atria Books, 2009.
8. Talbott, S., The Secret of Vigor: How to Overcome Burnout, Restore Metabolic Balance, and Reclaim Your Natural Energy, Hunter House, 2011.
9. Lee, C. D., Blair, S. N., Jackson, A. S., Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am. J. Clin. Nutr. 1999, 69, 373-380.
10. Manson, J. E., Greenland, P., LaCroix, A. Z., Stefanick, M. L. et al., Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N. Engl. J. Med. 2002, 347, 716-725.
11. Tanasescu, M., Leitzmann, M. F., Rimm, E. B., Willett, W. C. et al., Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002, 288, 1994-2000.
12. Myers, J., Exercise and cardiovascular health. Circulation 2003, 7, e2-5.
13. Williams, M. A., Haskell, W. L., Ades, P. A., Amsterdam, E. A. et al., Resistance exercise in individuals with and without cardiovascular disease: 2007 update. Circulation 2007, 116, 572-584.
14. Balakrishnan, V. S., Rao, M., Menon, V., Gordon, P. L. et al., Resistance training increases muscle mitochondrial biogenesis in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 996-1002.
15. Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C. et al., Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 2001, 345, 1291-1297.
16. Pilcher, J. J., Ginter, D. R., Sadowsky, B., Sleep quality versus sleep quantity: Relationships between sleep and measures of health, well-being and sleepiness in college students. J. Psychosom. Res. 1997, 42, 583-596.
17. Stratakis, C. A., Chrousos, G. P., Neuroendocrinology and pathophysiology of the stress system. Ann. N. Y. Acad. Sci. 1995, 771, 1-18.
18. Mayer, E. A., The neurobiology of stress and gastrointestinal disease. Gut 2000, 47, 861-869.
19. Rhee, S. H., Pothoulakis, C., Mayer, E. A., Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 306-314.
20. Childre, D. L., Martin, H., Beech, D., The HeartMath Solution: The Institute of HeartMath's Revolutionary Program for Engaging the Power of the Heart's Intelligence, HarperCollins, 2000.
21. Hood, L., Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306, 640-643.
22. Hood, L., Balling, R., Auffray, C., Revolutionizing medicine in the 21st century through systems approaches. Biotechnol. J. 2012, 7. DOI: 10.1002/biot/201100306.
23. Dawson-Hughes, B., Heaney, R. P., Holick, M. F., Lips, P. et al., Estimates of optimal vitamin D status. Osteoporos. Int. 2005, 16, 713-716.
24. Sears, B., The Anti-Aging Zone, HarperLuxe, 1999.
25. Polonsky, T. S., McClelland, R. L., Jorgensen, N. W., Bild, D. E., Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010, 303, 1610-1616.
26. da Luz, P. L., Favarato, D., Faria-Neto, J. R. Jr., Lemos, P., Chagas, A. C., High ratio of triglycerides to hdl-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008, 63, 427-432.
27. Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005, 112, 3375-3383.
28. Danesh, J., Collins, R., Peto, R., Lipoprotein(a) and coronary heart disease: Meta-analysis of prospective studies. Circulation 2000, 102, 1082-1085.
29. Deckers, J. W., Blumenthal, R. S., Statins for primary prevention of cardiovascular disease. BMJ 2011, 342, d1048.
30. Sears, B., The Anti-Inflammation Zone: Reversing the Silent Epidemic That's Destroying Our Health, William Morrow, 2005.
31. Simopoulos, A. P., Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21, 495-505.
32. Hill, A. M., Buckley, J. D., Murphy, K. J., Howe, P. R., Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am. J. Clin. Nutr. 2007, 85, 1267-1274.
33. Simopoulos, A. P., The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56, 365-379.
34. Lemaitre, R. N., King, I. B., Mozaffarian, D., Kuller, L. H., n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am. J. Clin. Nutr. 2003, 77, 319-325.
35. Simopoulos, A. P., The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. 2008, 233, 674-688.
36. Ridker, P. M., Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107, 363-369.
37. Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., Cook, N. R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002, 347, 1557-1565.
38. Libby, P., Ridker, P. M., Maseri, A., Inflammation and atherosclerosis. Circulation 2002, 105, 1135-1143.
39. Ridker, P. M., Cardiology Patient Page. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation 2003, 108, e81-e85.
40. Sutherland, A. D., Gearry, R. B., Frizelle, F. A., Review of Fecal Biomarkers in Inflammatory Bowel Disease. Dis. Colon Rectum 2008, 51, 1283-1291.
41. Dai, J., Liu, W. Z., Zhao, Y. P., Hu, Y. B., Ge, Z. Z., Relationship between fecal lactoferrin and inflammatory bowel disease. Scand. J. Gastroenterol. 2007, 1440-1444.
42. Vieira, A., Fang, C. B., Rolim, E. G., Klug, W. A., Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res. Notes. 2, 2009, 221.
43. Freeman, H. J., Crohn's disease initially diagnosed after age 60 years. Age Ageing 2007, 36, 587-589.
44. Walker, T. R., Land, M. L., Cook, T. M., Sandborn, W., et al., Serial fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive IBD. DDW (New Orleans) 2004, S1423.
45. Sartor, R. B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 390-407.
46. Abraham, C., Medzhitov, R., Interactions between the host innate immune system and microbes in IBD. Gastroenterology 2011, 140, 1729-1737.
47. Gut Microbiota. Science 2012, 336, 1245-1273.
48. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207-214.
49. Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012, 486, 215-221.
50. Manary, M. J., Trehan, I., Dominguez-Bello, M. G. et al., Contreras, M, Human gut microbiome viewed across age and geography. Nature 2012, 486, 222-227.
51. Stephen, A. M., Cummings, J. H., The microbial contribution ot human faecal mass. J. Med. Microbiol. 1980, 13, 45-56.
52. Jernberg, C., Löfmark, S., Edlund, C., Jansson, J. K., Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007, 1, 56-66.
53. Shaw, S. Y., Blanchard, J. F., Bernstein, C. N., Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 2011, 106, 2133-2142.
54. Qin, J., Li, R., Raes, J., Arumugam, M. et al., A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464, 59-65.
55. Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H. et al., A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122, 512-530.
56. Jansson, J., Willing, B., Lucio, M., Fekete, A. et al., Metabolomics reveals metabolic biomarkers of Crohn's disease PLoS One 2009, 4, e6386.
57. Willing, B. P., A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139, 1844-1854.
58. Radford-Smith, G., Pandeya, N., Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease - Are we there yet? World J. Gastroenterol. 2006, 12, 7097-7103.
59. van der Greef, J., Hankemeier, T., McBurney, R. N., Metabolomics-based systems biology and personalized medicine: Moving toward N=1 clinical trials? Pharmacogenomics 2006, 7, 1087-1094.
60. Watson, A. D., Lipidomics: A global approach to lipid analysis in biological systems. J. Lipid Res. 2006, 47, 2101-2111.
61. Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L. et al., Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148, 1293-1307.
62. Kinross, J. M., Darzi, A. W., Nicholson, J. K., Gut microbiome-host interactions in health and disease. Genome Med. 2011, 3, 14-26.
63. Sekirov, I., Russell, S. L., Antunes, L. C., Finlay, B. B., Gut microbiota in health and disease. Physiol. Rev. 2010, 90, 859-904.
64. Spor, A., Koren, O., Ley, R., Unravelling the effects of the environment and host genotype on the gut microbiome. Nat. Rev. Microbiol. 2011, 9, 279-290.